Guardant Health (GH) EPS (Weighted Average and Diluted) (2019 - 2026)

Guardant Health has disclosed EPS (Weighted Average and Diluted) across 8 years of filings, most recently posting -$0.85 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.85, down 10.39% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.39 (changed 0.0% YoY), and the FY2025 annual result was -$3.32, up 6.74% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.85 for Q1 2026 at Guardant Health, up from -$1.0 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.67 in Q2 2023 to a low of -$2.25 in Q2 2022.
• The 5-year median for EPS (Weighted Average and Diluted) is -$0.9 (2024), against an average of -$1.09.
• Across the five-year window, EPS (Weighted Average and Diluted) tumbled 134.38% in 2022 and surged 70.22% in 2023, its largest moves.
• Guardant Health's EPS (Weighted Average and Diluted) stood at -$1.37 in 2022, then declined by 18.25% to -$1.62 in 2023, then jumped by 44.44% to -$0.9 in 2024, then slipped by 11.11% to -$1.0 in 2025, then rose by 15.0% to -$0.85 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.85 (Q1 2026), -$1.0 (Q4 2025), and -$0.74 (Q3 2025), per Business Quant data.